Alphamab Oncology (HKG: 9966), a biopharmaceutical company, has announced that the first patient has been dosed in a Phase I clinical study for JSKN016, its innovative antibody-drug conjugate (ADC) targeting both HER3 and TROP2 in patients with solid tumors.
The open-label, multi-center Phase I study is designed to conduct a dosage escalation and expansion phase to evaluate the safety, tolerability, and anti-tumor activity of JSKN016. The trial aims to enroll between 80 to 140 patients and will also assess pharmacokinetics (PK) and immunogenicity of the drug candidate. A key objective of the study is to determine the maximal tolerable dose (MTD) and/or the recommended Phase II dose (RP2D) for future clinical trials.- Flcube.com
